General Commentary: Pluristem Therapeutics (PSTI) is trading notably higher today, following the news that the life of a patient suffering from bone marrow failure in which there was a dangerous reduction in the number of red blood cells, white blood cells, and platelets (pancytopenia) has been saved using Placental eXpanded (PLX) cells. Following the injection of the PLX cells intramuscularly (IM), the woman's clinical condition and blood counts improved to the point where the patient was able to be released from the isolation unit and subsequently discharged from the hospital. In May, Pluristem announced that a seven year-old girl, whose condition was rapidly deteriorating due to an aplastic bone marrow, experienced a reversal of her condition with a significant increase in her red blood cells, white blood cells and blood platelets following the intramuscular injection of the company's PLX cells. The patient has subsequently been released from the hospital and returned home. Pluristem recently announced it is preparing to apply for Orphan Drug Status for its PLX cells with the U.S. Food and Drug Administration for the treatment of aplastic bone marrow. The bone marrow transplant market is an estimated $1.3 billion per year in the U.S. alone, based on 30,000 bone marrow transplants in the U.S per annum.

Gainers on news: Pluristem Therapeutics (PSTI +19.82%) Reported that the life of a cancer patient suffering from bone marrow failure was recently saved using the company's Placental eXpanded cells OXiGENE (OXGN +13.73%) Announced Phase 2 ovarian cancer trial of ZYBRESTAT plus bevacizumab achieved an important interim safety objective and is expected to continue to full enrollment Rexahn Pharmaceuticals (RNN +6.33%) Completed its exploratory Phase 1 clinical trial of RX-3117 in cancer patients; the study demonstrated that RX-3117 is bioavailable when delivered orally to patients; no adverse events were reportedDecliners on news: Exelixis (EXEL -8.78%) Announced plans to offer 20 mln shares of its common stock and $225 mln aggregate principal amount of convertible senior subordinated notes due 2019 in concurrent underwritten public offerings Sarepta Therapeutics (SRPT -5.67%) Received a stop-work order from the Department of Defense with respect to the Ebola portion of the contract for Advanced Development of Hemorrhagic Fever Virus TherapeuticsGainers on earnings: ISIS Pharmaceuticals (ISIS +11.18%) Beat quarterly EPS by $0.07 (-$0.01 vs -$0.08 estimate), revenues rose 90.7% yoy to $47.3 mln vs $42.44 mln estimate Cleveland Biolabs (CBLI +2.68%) Reported Q2 EPS of -$0.14 vs -$0.04 estimate; revenues fell 47.3% yoy to $0.3 mln vs $5 mln estimateDecliners on earnings: HCA (HCA -6.32%) Beat quarterly EPS by $0.07 ($0.85 vs $0.78 estimate), revenues rose 11.9% yoy to $8.11 mln, may not compare to $8.82 mln estimate; reaffirmed FY12 EPS of $3.57-3.77 vs $3.58 estimate, sees FY12 revs of $32-33 bln vs $35.26 bln estimate

Upgrades/Downgrades: Endologix (ELGX +4.72%) Upgraded to Buy from Neutral at Lazard Edwards Lifesciences (EW -0.68%) Downgraded to Outperform at RBC Capital Amarin (AMRN -4.86%) Hearing cautious comments from Summer Street: risk of low launch and generic competition.

General Commentary: Pluristem Therapeutics (PSTI) is trading notably higher today, following the news that the life of a patient suffering from bone